Reprocell
Biotechnology, 505 N 6th St, Yokohama, Indiana, 47591, United States, 51-200 Employees
Phone Number: 81*********
Who is REPROCELL
REPROCELL supports nearly the entire workflow of stem cell research and pre-clinical drug development. Our unique portfolio includes access to human tissues (BioServe) and human tissue te...
Read More
-
Headquarters: 505 N 6th St, Yokohama, Indiana, 47591, United States
-
Date Founded: 2003
-
Employees: 51-200
-
Revenue: $50 Million to $100 Million
-
Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 2835
|
NAICS Code: 325413 |
Show More
REPROCELL Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding REPROCELL
Answer: REPROCELL's headquarters are located at 505 N 6th St, Yokohama, Indiana, 47591, United States
Answer: REPROCELL's phone number is 81*********
Answer: REPROCELL's official website is https://reprocell.co.jp
Answer: REPROCELL's revenue is $50 Million to $100 Million
Answer: REPROCELL's SIC: 2835
Answer: REPROCELL's NAICS: 325413
Answer: REPROCELL has 51-200 employees
Answer: REPROCELL is in Biotechnology
Answer: REPROCELL contact info: Phone number: 81********* Website: https://reprocell.co.jp
Answer: REPROCELL supports nearly the entire workflow of stem cell research and pre-clinical drug development. Our unique portfolio includes access to human tissues (BioServe) and human tissue testing (Biopta), in addition to stem cell culture media, reprogramming technologies, reagents, and iPSC-derived cell types (Stemgent). With our deep knowledge of stem cell biology, bioengineered (3D) tissue models (Alvetex) cell differentiation, and pharmacology, REPROCELL is a recognized leader in cutting-edge tools and services to accelerate regenerative medicine and drug development. The newly formed REPROCELL Medical business unit is developing a suite of reagents and services to meet the growing need for clinical-grade products and services that are appropriate for regenerative medicine. In addition, our labs offer diagnostic services for a variety of tests related to tissue compatibility and other biomarkers. And finally, REPROCELL also offers a GMP iPSC master cell bank manufacturing service. *** REPROCELL went public on the Japan JASDAQ in June 2013. Stemgent, BioServe and Reinnervate became parts of REPROCELL in 2014. Biopta was then acquired in 2015.
Answer:
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month